Evidence map›Paper›PMID 34739591›Full record

ArticleEuropean journal of pediatrics2022

Development of the Swiss Database for dosing medicinal products in pediatrics.

Romy Tilen, Dalibor Panis, Samuel Aeschbacher, Thomas Sabine, Henriette E Meyer Zu Schwabedissen, Christoph Berger

Erratum issuedOpen access · hybridAbstract read
In one paragraph

Article in European journal of pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
7.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Neonatal Drug Formularies-A Global Scope.Children (Basel, Switzerland) · 2023
    Article
  9. Article
  10. SwissPKCPT: pharmacometrics & systems pharmacology · 2021
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Romy TilenSwissPedDose, Zurich, Switzerland. romy.tilen@swisspeddose.ch.ORCID http://orcid.org/0000-0002-1627-1513
Dalibor PanisSwissPedDose, Zurich, Switzerland.
Samuel AeschbacherInfoserv, Evilard, Switzerland.
Thomas SabineFederal Office of Public Health, Bern, Switzerland.
Henriette E Meyer Zu SchwabedissenBiopharmacy, Department of Pharmaceutical Science, University Basel, Basel, Switzerland.
Christoph BergerSwissPedDose, Zurich, Switzerland.
Federal Office of Public Health · CHUniversity Children's Hospital Zurich · CHUniversity of Basel · CH

Funding

Bundesamt für Gesundheit N/AConference of Cantonal Health Directors N/A
6 · The paper itself

Abstract

In daily paediatrics, drugs are commonly used off-label, as they are not approved for children. Approval is lacking because the required clinical studies were limited to adults in the past. Without clinical studies, evidence-based recommendations for drug use in children are limited. Information on off-label drug dosing in children can be found in different handbooks, databases and scientific publications but the dosing recommendations can differ considerably. To improve safety and efficacy of drugs prescribed to children and to assist the prescribers, stakeholders in Swiss paediatrics started a pilot project, supported by the Federal Office of Public Health, with the aim to create a database, providing healthcare professionals with so called "harmonised" dosage recommendations based on the latest available scientific evidence and best clinical practice. A standardised process for dosage harmonisation between paediatric experts was defined, guided and documented in an electronic tool, developed for this purpose. As proof of principle, a total of 102 dosage recommendations for 30 different drugs have been nationally harmonised in the pilot phase considering the current scientific literature and the approval of the most experienced national experts in the field.Conclusion: This approach paved the way for unified national dosage recommendations for children. Reaching the project's milestones fulfilled the prerequisites for funding and starting regular operation of SwissPedDose in 2018. Since then, the database was extended with recommendations for 100 additional drugs. What is Known: • Prescribing off-label is a common practice among paediatricians, as many drugs are still not authorised for use in children. • Some countries developed national drug formularies providing off-label dosage recommendations. What is New: • Comparison of published dosage recommendations in known drug handbooks and online databases show substantial differences and heterogeneity, revealing the need for harmonisation. • The design of a tool for standardised harmonisation of dosage recommendations, based on information collected on currently applied dosages, latest scientific evidence and the approval of experts.

Indexed as

Databases, PharmaceuticalOff-Label UsePediatricsAdultChildDrug LabelingHumansPilot ProjectsSwitzerlandChildrenDrug safetyOff-label usePrescribingWeb-based software

Identifiers

PMID34739591
PMCPMC8897330
OpenAlexW3208742427

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.